Incyte Publicizes Constructive Outcomes from Section 3 Trial Evaluating Retifanlimab (Zynyz ®) in Mixture with Platinum-Primarily based Chemotherapy in Sufferers with Non-Small Cell Lung Most cancers By Investing.com
” Section 3 POD1UM-304 trial met main endpoint of general survival (OS)…
Incyte earnings missed by $2.69, income topped estimates By Investing.com
Investing.com - Incyte (NASDAQ: ) reported second quarter EPS of $-1.82, $2.69…
